Trial Profile
A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms LOGiC
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; Novartis; Novartis Pharmaceuticals
- 02 Apr 2024 Planned End Date changed from 23 May 2024 to 22 Aug 2024.
- 15 Jan 2024 Planned End Date changed from 29 Feb 2024 to 23 May 2024.
- 12 Sep 2023 Planned End Date changed from 29 Dec 2023 to 29 Feb 2024.